Semaglutide in the FATZO Mouse: A New Mouse Model of Type II Diabetes
Richard G Peterson, Charles V Jackson, Karen Zimmerman, Tamer Coskun*, and Paul Emmerson*
*Eli Lilly and Co, Indianapolis, IN
Glucagon-like Peptide-1 (GLP-1) receptor agonists, e.g. semaglutide, improve glucose homeostasis and reduce body weight in humans and in mouse models of Type II diabetes.
CrownBio has developed the MS-NASH (formerly called FATZO) Type II diabetes model, selectively bred for obesity, insulin resistance, and hyperglycemia, whilst maintaining an intact leptin pathway and fed normal chow. The MS-NASH (FATZO) mouse has now been studied to demonstrate its value in the preclinical screening of GLP-1 receptor agonists.
Read this Poster to Discover:
- That semaglutide demonstrates anti-diabetic and anti-obesity efficacy in the MS-NASH (FATZO) mouse
- The dose dependent decreases in both food consumption and body weight observed, as well as insulin resistance improvement
- How the benefits of semaglutide in the MS-NASH (FATZO) mouse may provide a model highly translatable to human diabetes and obesity